LFB
30.9.2013 08:01:13 CEST | Business Wire | Pressemeddelelse
The biotechnologies company GamaMabs Pharma was launched and financed with LFB and BpiFrance‘s participation through Innobio fund next to IRDINov and iXO Private Equity in order to develop new cancer therapies. The company’s first product is a new monoclonal antibody targeting gynecological cancers, including ovarian cancer.
Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States. It has a poor prognosis as it is often diagnosed at an advanced stage due to a lack of systematic screening. Increasing resistance to traditional chemotherapy treatments justifies research into targeted therapeutic solutions, such as monoclonal antibodies.
In collaboration with public partners (Inserm, Université de Montpellier; Institut du cancer de Montpellier), the LFB group has chosen an original antibody with strong cytotoxic activity from its propriety platform for the monoclonal antibody generations (EMABling®), to provide a new therapeutic approach to this pathology. The antibody 3C23K, for which LFB has obtained an exclusive operating license, has proven its effectiveness in experimental models of ovarian cancer.
Dr Jean-François Prost, former Scientific and medical director of the LFB group, and Stéphane Degove have joined forces to create GamaMabs Pharma and raise the necessary funds to develop this program.
GamaMabs Pharma benefits from an exclusive global sublicense from the
LFB group for the monoclonal antibody 3C23K and is supported by LFB
group’s EMABling® platform. In exchange for the agreed rights, LFB group
owns a minor participation in the capital of GamaMabs Pharma. Led by
BpiFrance through Innobio fund, the venture capital funds will
contribute up to 3.1 million euros to the deal.
This investment
will allow the validation of the therapeutic concept, in collaboration
with various regional centers specialized in the fight against cancer
and to prepare the first clinical trial.
Denis Soubeyran, Head of finance and strategy of LFB group has declared: “This contract provides every opportunity for the success of this very promising project, initiated by LFB group, for the treatment of ovarian cancer. Our capital contribution in GamaMabs Pharma, our implication in the project through our EmaBling® platform and the bioproduction capacity of our subsidiary LFB Biomanufacturing all demonstrate our interest and confidence in the future of this project”.
Philippe Boucheron, Deputy Director of Life Sciences at Bpifrance Investissement has declared: “BpiFrance is delighted to work with GamaMabs Pharma and to support a truly innovative therapeutic approach for ovarian cancer, a cancer for which, sadly, few new solutions have reached the market recently and for which medical attention is important. Stéphane Degove and Jean-François Prost have the ideal combined experience to give GamaMabs Pharma the best chance of success”.
“We are extremely motivated by the development of this first-in-class antibody and our aim is to launch clinical trials in 2015”, added Stéphane Degove and Jean-François Prost. “In addition to the financial support from key investors in the Health sector, this programme benefits from the R&D expertise of the LFB group”.
The management team at GamaMabs Pharma
Dr Jean-François
Prost, Vice President of R&D and Strategy at GamaMabs Pharma has 30
years of experience in the European pharmaceutical industry. Previously
he led the R&D Departments of Servier, Pierre Fabre and UCB Pharma. Over
the past ten years as Scientific and medical director at LFB, he has
determinedly contributed to the development of EMABling® technology and
to that of two antibodies currently in the clinical development.
Stéphane Degove, Chief Executive Officer of GamaMabs pharma, has 17 years of experience in Finance and Strategy in the pharmaceutical and biotechnology industries. An ESCP Europe graduate, he has worked for Sanofi and was a co-founder of Endotis Pharma specializing in thrombosis and cancer.
About the LFB group
LFB is a
French biopharmaceutical group that develops, manufactures and
commercializes/ markets medication for serious and often rare
pathologies in the following major therapeutic fields: immunology,
intensive care and hemostasis.
The LFB group is number one in
France and number five in the world in plasma-derived medicinal
products. The group is also one of the top European companies in the
development and production of proteins and new generation treatments in
biotechnologies. In 2012, 76.7 million euros were put towards research
and development, for a turnover of 465.7 million euros.
Christian
Béchon is the President of the group, which has 1887 employees.
http://www.lfb.fr
About Bpifrance and InnoBio
Bpifrance’s
equity investments are operated by Bpifrance Investissement. Bpifrance
invests directly or indirectly has a minority party through partner’s
equity, in French companies, PME, ETI and larger companies.
InnoBio
is a 139 million euro FCPR managed by Bpifrance and subscribed by the
FSI (37%) and the key global pharmaceutical companies (Sanofi Aventis,
GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda,
Boehringer-Ingelheim) operating in France.
The main objective of
the fund is to directly invest equity or partial equity in the capital
of firms who provide innovative and technological products and services
in the Health sector.
InnoBio, is made up of a team of investors
specialised in the industry and has to this day made 13 investments of a
total of 65 million euros.
www.bpifrance.fr
About IRDInov
IRDInov
is
an interregional seed fund, launched in late 2012 with the support of
the FNA (National Seed Fund) and managed by CDC Enterprises, IRDI, and
the Midi-Pyrénées and Aquitaine Regions alongside partnerships with
regional banks and industrials.
The investment strategy of the fund is centered on spin-off projects
from public or private research organisms in all innovative and
industrial sectors. IRDInov invests (through several fundraising
rounds), sums ranging from 500K euro to 3 million euros in innovative
companies in seed or start-up stages, located in Aquitaine,
Midi-Pyrénées and Limousin.
The fund, managed by the GIE IRDI, was
granted 25.2 million euros in its first round with an aim to raise an
additional 10 million euros.
About IXO PE
IXO private Equity
is an independent company 100 % held by its management team.
It
manages an asset portfolio in capital-investment of 323M€.
The
funds made out from type FIP/FCPI's public offer represent 155M€. FCPR's
funds signed mainly by institutional rise represent, as for them, 168M€.
Located
in Toulouse, IXO Private Equity invests equity in PME located in the
South of France (south east – south-west)
www.ixope.fr
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130929005017/en/
Contact:
GamaMabs Pharma
Stéphane Degove, +33 1 70 96 00 67
CEO
sdegove@gamamabs.com
Jean-François
Prost, +33 1 70 96 00 68
VP R&D and strategy,
jfprost@gamamabs.com
or
LFB group
Sandrine
Charrières, + 33 1 69 82 72 80
Corporate communications
director
charrieres@lfb.fr
or
IRDInov
Jean-Michel
Petit, Tel : +33 05 81 317 320
jean.michel.petit@irdi.fr
or
IXO
PE
+33 5 34 417 418
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Venture Global Announces Closing of $2.25 Billion of Senior Secured Notes11.6.2026 23:00:00 CEST | Press release
Venture Global LNG, Inc. (“Venture Global”) announced today that its wholly-owned subsidiary, Venture Global LNG, Inc. (the “Issuer”) has closed its offering of $1.125 billion aggregate principal amount of its 6.375% senior secured notes due 2034 (the “2034 Notes”) and $1.125 billion aggregate principal amount of its 6.625% senior secured notes due 2036 (the “2036 Notes” and, together with the 2034 Notes, the “Notes”). The Issuer used the gross proceeds from the offering to redeem all of the Issuer’s outstanding 8.125% senior secured notes due 2028 (the “Existing 2028 Notes”) and used cash on hand to pay the redemption premium and related fees and expenses for the offering and the redemption. The 2034 Notes will mature on December 15, 2034, and the 2036 Notes will mature on June 15, 2036. The Notes were issued at par. The Notes will initially not be guaranteed by any of the Issuer’s subsidiaries. In the future, certain of the Issuer’s subsidiaries that incur or guarantee certain amount
Venture Global and Atlantic-SEE Announce Expansion of Long-Term LNG Sales and Purchase Agreement with Greece11.6.2026 22:30:00 CEST | Press release
Deal doubles quantity of US LNG to be supplied by Venture Global, expanding existing partnership to bolster Central and Eastern European energy securityBuilds on Venture Global’s regasification capacity investment in the Alexandroupolis LNG import terminal to supply U.S. LNG to the region Today, Venture Global, Inc. (NYSE: VG) and ATLANTIC – SEE LNG TRADE S.A. of Greece announced an expansion of their existing Sales and Purchase Agreement (SPA) for the purchase of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. Under the deal, Atlantic-SEE is doubling their existing contract with Venture Global from a minimum of 0.5 million tonnes per annum (MTPA) to 1.0 million tonnes per annum (MTPA). Atlantic-SEE LNG is a newly formed joint venture announced in November at the 6th Partnership for Transatlantic Energy Cooperation (PTEC) conference hosted in Athens, Greece between Greek companies AKTOR Group and DEPA Commercial. The announcement of this expanded
Merrithew® Expands Global Mindful Movement Leadership with Acquisition of the GYROTONIC® Organization11.6.2026 17:30:00 CEST | Press release
Strategic acquisition strengthens Merrithew International Inc.’s position as a leading global authority in mindful movement education, equipment, and wellness Merrithew®, a global leader in mindful movement education and equipment and creator of internationally recognized programs including STOTT PILATES®, ZEN•GA®, Halo® Training and Total Barre®, today announced the acquisition of the GYROTONIC® organization, creator of the globally respected GYROTONIC® and GYROKINESIS® methods. Founded by Juliu Horvath, the GYROTONIC® and GYROKINESIS® methods are internationally recognized for their distinctive approach to movement, combining fluidity, strength, mobility, coordination, and rehabilitation through specialized equipment and movement sequences. Practiced in studios and wellness centers worldwide, the methods have cultivated a deeply loyal global community of instructors, trainers, therapists, and movement professionals. The acquisition marks a significant milestone in Merrithew Internati
GigaDevice Expands Optical Communication Portfolio with New GD32E512 and GD32E252 Series MCUs for Optical Modules11.6.2026 16:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has introduced the new GD32E512 and GD32E252 series MCUs specifically designed for optical module applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611850679/en/ Empowering Optical Interconnect Innovation, GigaDevice Unveils Dedicated MCUs for Optical Modules. As a leading supplier of MCUs for optical module applications, GigaDevice has maintained a strong focus on the optical communication market, continuously aligning its product development with evolving industry requirements and next-generation optical interconnect technologies. Leveraging years of expertise in optical module control solutions, GigaDevice has established a strong position in the market through continuous innovation and close collaboration with industry partners. To further support the advancement of high-sp
Saudi Arabia at the Center of the Global Water Industry as IDWS 2026 Reshapes the Future of Water11.6.2026 15:47:00 CEST | Press release
In an increasingly resource-constrained world, water has become critical to both economic growth and national security, driving demand for global leadership in sustainability, innovation, and water solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611388456/en/ Saudi Arabia at the Center of the Global Water Industry as IDWS 2026 Reshapes the Future of Water (Graphic: AETOSWire) The Saudi Water Authority has announced the return of the Innovation Driven Water Sustainability Conference (IDWS), taking place from 7 to 9 December 2026 at The Ritz-Carlton, Jeddah, as the Kingdom consolidates its position at the center of the global water conversation. As home to one of the world’s most advanced and rapidly evolving water management ecosystems, Saudi Arabia currently operates more than 500 water production facilities across the Kingdom with total water production capacity exceeding 16.2 million cubic meters per day. The
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum